Lagos Raises HIV Budget by 35% to ₦1.065bn, Begins Buying Its Own Treatment Drugs

Share
Lagos Raises HIV Budget by 35%, Begins Local Purchase of HIV Drugs

LAGOS, Nigeria – Lagos State has increased its HIV budget by 35 per cent to ₦1.065 billion in 2026 and begun distributing government-procured antiretroviral medicines as it moves to reduce dependence on external funding.

Chief Executive Officer of the Lagos State AIDS Control Agency (LSACA), Dr Folakemi Animashaun, announced this on Thursday during a press briefing ahead of the 2026 World AIDS Day. She said the allocation increased from approximately ₦791 million, adding that stronger domestic financing was necessary to protect treatment services amid changing global funding conditions.

Animashaun also announced plans for a 10-year HIV Response Transition and Sustainability Roadmap covering 2027 to 2036. The proposed framework will address local financing, healthcare delivery, medicine and diagnostic supplies, staffing, community participation and accountability. The roadmap is expected to be presented by Governor Babajide Sanwo-Olu on December 1, subject to approval.

Providing programme figures, Animashaun reported 7,584 positive and 387,558 negative HIV test results. She stressed that these represented reported results, not necessarily unique individuals or newly diagnosed infections. Between January and October, 25,167 HIV tests among people aged 15 and above produced 1,166 positive results.

She identified stigma, discrimination and financial constraints as barriers to accessing services, urging residents to seek testing and prevention options, including condoms, pre-exposure prophylaxis and post-exposure prophylaxis where medically indicated. Animashaun also reaffirmed that people living with HIV who maintain an undetectable viral load through effective treatment cannot transmit the virus sexually. The state said the initiative formed part of efforts to sustain treatment access and strengthen its HIV response.

Join the conversation

Leave a comment

Your email address will not be published. Please keep it civil and on topic.

You May Have Missed